Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review

Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review

IntroductionMetastatic uveal melanoma (mUM) is a difficult to treat disease. The liver is the primary site of metastasis in most patients, though uveal melanoma spreads widely in advanced disease. The only FDA approved immunotherapy medication for metastatic uveal melanoma is the HLA-A02:01 restrict...

Full description

Bibliographic Details
Main Authors: Danielle H. Tran, Ryan Shanley, Alessio Giubellino, Peter H. Tang, Dara D. Koozekanani, Jianling Yuan, Kathryn Dusenbery, Evidio Domingo-Musibay
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-07-01
Series:Frontiers in Oncology
Subjects:
metastatic uveal melanoma
immunotherapy
radiation therapy (radiotherapy)
retrospective study
ipilimumab
nivolumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1406872/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1406872/full

Similar Items